Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

71.21 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 4, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 360
Open 71.21
Bid (Size) 71.10 (1)
Ask (Size) 71.33 (1)
Prev. Close 71.21
Today's Range 71.21 - 71.21
52wk Range 53.22 - 80.59
Shares Outstanding 2,222,113,553
Dividend Yield 2.75%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Best Stocks 2022: These 3 Factors Can Send Sonic Automotive (SAH) Stock Soaring in Q4
While Sonic Automotive isn’t in the lead for the top 10 best stocks ranking, SAH stock performs relatively well because of its fundamentals. 
Via InvestorPlace
Autolus Therapeutics Stock Jumps After Bristol Myers Pact For Safety Switch System
 
Via Benzinga

Performance

YTD
+15.08%
+15.08%
1 Month
+3.73%
+3.73%
3 Month
-6.25%
-6.25%
6 Month
-4.33%
-4.33%
1 Year
+20.84%
+20.84%

More News

Read More
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
From Autolus Therapeutics plc
Via Globe NewsWire
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio
Via Talk Markets
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
Via Benzinga
Bristol Myers' Opdivo Combo Treatment Scores European Approval For Skin Cancer Setting
Via Benzinga
Insiders Selling Nasdaq, Bristol-Myers Squibb And This Consumer Defensive Stock
Via Benzinga
Bristol-Myers Squibb, Cash, Cheniere Energy And This Tech Company Are CNBC's Final Trades
Via Benzinga
Salesforce Is Among Thursday's CNBC 'Fast Money' Final Trades
Via Benzinga
Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial
Via Benzinga
3 Stocks That Could Rocket on Biden’s Cancer Moonshot
Via InvestorPlace
What Are Whales Doing With Bristol-Myers Squibb
Via Benzinga
Amazon, Target And 3 Other Stocks Insiders Are Selling
Via Benzinga
7 Penny Stocks That Actually Have a Buy Rating
Via InvestorPlace
US Stock Futures Down Ahead Of Fed's Rate Decision This Week, Crude Oil Drops Over 1%
Via Benzinga
AutoZone, bluebird bio And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%
From Bristol Myers Squibb
Via Business Wire
Top US Drugmakers Exploit US Patent System To Keep Generic Competition At Bay: Report
Via Benzinga
Looking At Bristol-Myers Squibb's Recent Whale Trades
Via Benzinga
Bristol-Myers Squibb And 2 Other Stocks Insiders Are Selling
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
Via Investor's Business Daily
Melanoma Study Achieves Key Milestone as Bristol's Flagship Treatment Secures Improvement in Survival Rates
Via Benzinga
Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.